From GlobeNewswire:

TG Therapeutics, Inc. announced preliminary U.S. net product revenue for BRIUMVI® for the fourth quarter and full year ended December 31, 2023, totaling approximately $40 million and $89 million, respectively. The year-end 2023 cash position is approximately $215 million. The company has set a 2024 target operating expense of approximately $250 million, and has announced several development pipeline milestones for the coming year. Additionally, BRIUMVI is contraindicated in patients with active Hepatitis B Virus infection and a history of life-threatening infusion reactions. The medication can cause infusion reactions, infections, and Hepatitis B Virus reactivation, among other side effects.



Read more: TG Therapeutics Provides Preliminary Fourth Quarter and